DRI Healthcare Trust price target raised to C$19 from C$18 at RBC Capital

Published 12/06/2025, 13:26
DRI Healthcare Trust price target raised to C$19 from C$18 at RBC Capital

RBC Capital raised its price target on DRI Healthcare Trust (TSX:DHT.U) to C$19 from C$18 on Monday, while maintaining an Outperform rating on the stock.

The firm’s updated valuation follows data releases at the American Society of Clinical Oncology (ASCO) Annual Meeting earlier this month that highlighted potential increased competition for Orserdu, DRI’s largest royalty asset. RBC Capital continues to maintain its outlook for Orserdu, with peak revenues expected in 2025.

RBC Capital noted that discussions with Menarini management indicate continued optimism about Orserdu’s prospects, with expectations to sustain and potentially grow U.S. sales despite the evolving competitive landscape. The analyst firm, however, believes this growth could be challenging given the competitive environment.

The price target increase results from RBC Capital’s transition to a discounted cash flow (DCF) valuation model and the incorporation of future royalty transactions into its analysis. This methodological change accounts for the C$1 per unit increase in the target price.

DRI Healthcare Trust, which focuses on acquiring healthcare royalty assets, continues to receive a positive outlook from RBC Capital despite the competitive challenges facing its key asset Orserdu.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.